MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage numerous intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial goals have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when among the explorator... https://friedrichp888doy0.sasugawiki.com/user